BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FDA Accepts Noven Pharmaceuticals Inc.s NDA for an Investigational Nonhormonal Therapy for Menopausal Vasomotor Symptoms


11/13/2012 9:05:31 AM

MIAMI, FL and NEW YORK, NY, Nov. 12, 2012 /PRNewswire/ -- Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that its New Drug Application (NDA) for low-dose mesylate salt of paroxetine (LDMP; 7.5 mg) for the treatment of moderate to severe vasomotor symptoms (hot flashes and night sweats) due to menopause has been accepted for filing by the U.S. Food and Drug Administration (FDA). 

The acceptance of the NDA reflects the FDA's determination that the application is sufficiently complete to permit a substantive review. The NDA has been assigned a Prescription Drug User Fee Act (PDUFA) action date of June 28, 2013, which represents the goal date for the FDA to complete its review of the NDA.

In addition, the FDA advised Noven that the NDA for LDMP will be discussed at a meeting of the FDA's Reproductive Health Drugs Advisory Committee tentatively scheduled for March 4, 2013. 

Low-dose mesylate salt of paroxetine (LDMP) is an investigational oral nonhormonal therapy using 7.5 mg of paroxetine mesylate that was specifically developed for the treatment of vasomotor symptoms due to menopause. Noven submitted the LDMP NDA in August 2012. 

About Noven

Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of prescription pharmaceutical products. Noven is committed to developing and offering products and technologies that meaningfully benefit patients, its customers and its industry partners. Noven is a stand-alone operating subsidiary of Japan-based Hisamitsu Pharmaceutical Co., Inc., and serves as Hisamitsu's U.S. growth platform in prescription pharmaceuticals. For more information about Noven, visit www.noven.com. For information about Hisamitsu, visit www.hisamitsu.co.jp/english.

Contact

Joseph C. Jones
Vice President Corporate Affairs
Noven Pharmaceuticals, Inc.
305-253-1916

 

SOURCE Noven Pharmaceuticals, Inc.



Read at BioSpace.com

   
Menopause

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES